Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)–mutant astrocytoma may indicate radiation necrosis
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyae151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Yukie Ozeki und 18 weiteren Autor:innen. Beteiligte Einrichtung: Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Astrocytoma, Isocitrate Dehydrogenase, Brain Neoplasms, Radiation Injuries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: AMED.
Abstract (Originalsprache)
Background
Isocitrate dehydrogenase–mutant astrocytoma without cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion typically follows a slow clinical course. However, some cases show early progression on magnetic resonance imaging, and these characteristics remain under-reported. This study aimed to elucidate the characteristics of isocitrate dehydrogenase–mutant astrocytoma showing early progression on magnetic resonance imaging.
Methods
This retrospective study included 52 cases of primary astrocytoma, isocitrate dehydrogenase–mutant, Central Nervous System (CNS) 5 World Health Organization grade 2–3 according to the World Health Organization 2021 classification. Patients underwent surgery followed by radiation therapy and/or chemotherapy at our institution from 2006 to 2019. Progression-free survival and overall survival were analyzed.
Results
There were 24 and 28 grade 2 and grade 3 astrocytomas, respectively. The median patient age was 38 years. Forty-three patients underwent radiotherapy. Progression was diagnosed by magnetic resonance imaging in 22 patients with initial radiotherapy. Thirteen of the 22 patients underwent surgery, and seven of the 13 patients received surgery within 24 months of the initial radiotherapy. Histopathologically, radiation necrosis was confirmed in four of these seven patients (57.1%). The true progression-free survival rate, excluding radiation necrosis, at 2 years after surgery was 91.3% for grade 2 astrocytoma and 88.5% for grade 3 astrocytoma. The 5-year overall survival rate was 85.7% for grade 2 tumours and 76.4% for grade 3 tumours.
Conclusions
Radiation necrosis should be considered in cases showing early progression of isocitrate dehydrogenase–mutant astrocytoma, and a second surgery should be performed to confirm true recurrence or radiation necrosis. Astrocytomas with telomerase reverse-transcriptase promoter mutations may relapse relatively early and should be followed up with caution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Neurosurgery, Saitama Cancer Center, Saitama, Japan.
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
- Department of Neurosurgery, Tokai University School of Medicine, Isehara, Japan.
- Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Makoto Ohno, Hiroshi Igaki, Yuko Kubo, Yoshitaka Narita
Förderung
- AMED
Zitieren
APA
Ozeki, Y., Honda-Kitahara, M., Yanagisawa, S., Takahashi, M., Ohno, M., Miyakita, Y., Kikuchi, M., Nakano, T., Hosoya, T., Sugino, H., Satomi, K., Yoshida, A., Igaki, H., Kubo, Y., Ichimura, K., Suzuki, H., Masutomi, K., Kondo, A., & Narita, Y. (2025). Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)–mutant astrocytoma may indicate radiation necrosis. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae151
Vancouver
Ozeki Y, Honda-Kitahara M, Yanagisawa S, Takahashi M, Ohno M, Miyakita Y, et al. Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)–mutant astrocytoma may indicate radiation necrosis. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyae151
BibTeX
@article{Ozeki2025,
author = {Ozeki, Yukie and Honda-Kitahara, Mai and Yanagisawa, Shunsuke and Takahashi, Masamichi and Ohno, Makoto and Miyakita, Yasuji and Kikuchi, Miu and Nakano, Tomoyuki and Hosoya, Tomohiro and Sugino, Hirokazu and Satomi, Kaishi and Yoshida, Akihiko and Igaki, Hiroshi and Kubo, Yuko and Ichimura, Koichi and Suzuki, Hiromichi and Masutomi, Kenkichi and Kondo, Akihide and Narita, Yoshitaka},
title = {Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)–mutant astrocytoma may indicate radiation necrosis},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyae151}
}
EUVIMED